Alain Beck
Senior Director Biologics CMC & Developability Pierre Fabre
Dr Alain Beck is Senior Director, Biologics CMC and Developability (Pierre Fabre), co-founder and Associate Editor of mAbs journal (2009) and chairman of MabDesign SAB (2014). He is or was involved in +12 clinical stage biologics programs including dalotuzumab (Merck), telisotuzumab (telisotuzumab vedotin (Emrelis) and adizutecan/ cMet (AbbVie)), h515H7 mAb, lonigutamab (Acelyrin) and lonigutamab ugodotin ADC/ IGF1R, W0180 Vista IO mAb (PF), VERT-002/ cMet (Vertical Bio) and efsudenermin alpha (Esperare Foundation). He is author/ co-author of +270 publications (h-index: 77; +20,200 citations). He has contributed to +300 scientific meetings worldwide as chairman, invited keynote speaker, panellist, moderator, advisor, and/or organizer. He was the winner of 6th WADC (2019). He is member of the MAB Working Party (PhEur) and involved in scientific workshops with ANSM, EU, EMA, FDA, NIST, USP and WHO.
Seminars
- Establish rigorous validation frameworks that identify the 50% of AI outputs that are hallucinations, ensuring your teams trust and adopt computational tools rather than dismissing them due to poor early experiences
- Learn how to benchmark AI predictions against experimental data, understanding which use cases deliver value and which remain aspirational
- Discover strategies to educate scientific teams on AI capabilities and limitations, setting realistic expectations and driving productive adoption while avoiding the “magic bullet” trap
